ReviewDrug safety2019
Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
Robert Battat et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this papercites it
ReviewDrug safety2019
Robert Battat et al.PubMed ↗Publisher ↗
No numbers read from the abstract.